Lead Product(s) : TRS01
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tarsier Pharma Receives FDA Agreement for Tarsier-04 Phase 3 Trial of TRS01
Details : TRS01 (dazdotuftide) is a first-in-class NF-κB signaling pathway inhibitor, which is under phase 3 clinical development for the treatment of non-infectious uveitis including uveitic glaucoma.
Product Name : TRS01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 16, 2024
Lead Product(s) : TRS01
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TRS01
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tarsier Pharma Announces Successful Type C Meeting with FDA for TRS01 in Noninfectious Uveitis
Details : TRS01 (dazdotuftide) is a bio-inspired novel proprietary technology platform, based on a New Chemical Entity (NCE) with a disruptive mechanism of action that modulate macrophages from inflammatory macrophages (M1) to IL-10 secreting ant-inflammatory macr...
Product Name : TRS01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 13, 2023
Lead Product(s) : TRS01
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TRS01
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TRS01 (dazdotuftide) is a bio-inspired novel proprietary technology platform, based on a New Chemical Entity (NCE) with a disruptive mechanism of action that modulate macrophages from inflammatory macrophages (M1) to IL-10 secreting ant-inflammatory macr...
Product Name : TRS01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 23, 2023
Lead Product(s) : TRS01
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pilocarpine Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Accepts Orasis Pharmaceuticals' New Drug Application for CSF-1 for the Treatment of Presbyopia
Details : CSF-1 is a preservative-free formulation of low-dose pilocarpine, a muscarinic cholinergic agonist used on the eye to treat elevated intraocular pressure, various types of glaucoma, and to induce miosis. It is being investigated for the treatment of pres...
Product Name : Qlosi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 21, 2023
Lead Product(s) : Pilocarpine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TRS01
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TRS01 is a potent fast-acting immunomodulator, delivered as eye drops, for the treatment of non-infectious anterior uveitis in patients with uveitic glaucoma – that is considered an end-stage condition of uveitis.
Product Name : TRS01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 08, 2022
Lead Product(s) : TRS01
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pilocarpine Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Two presentations on Phase 2b clinical trial show CSF-1 met primary endpoints and achieved statistically significant and clinically meaningful improvements in distance-corrected near visual acuity (DCNVA) for participants with presbyopia.
Product Name : Qlosi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 23, 2022
Lead Product(s) : Pilocarpine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CSF-1
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Orasis Pharmaceuticals Concludes Phase 3 Clinical Trials for Presbyopia Candidate
Details : By repurposing existing and well-studied molecules, CSF-1 is designed to be effective, safe, comfortable, and easy-to-use, corrective eye drop for the treatment of presbyopia as an alternative to reading glasses.
Product Name : PresbiDrops
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 15, 2022
Lead Product(s) : CSF-1
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TRS01
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TRS01 is a potent fast-acting immunomodulator, delivered as eye drops, for the treatment of non-infectious anterior uveitis in patients with uveitic glaucoma.
Product Name : TRS01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 22, 2021
Lead Product(s) : TRS01
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable